COVID-19 Vaccine Candidate Found Effective

New York-based Pfizer Inc. and Germany's BioNTech SE announced their mRNA-based vaccine candidate, BNT162b2, targetted against the SARS-CoV-2 coronavirus, has demonstrated evidence of efficacy against COVID-19 in participants, without prior evidence of SARS-CoV-2 infection.

This finding is based on the first interim efficacy analysis conducted on November 8, 2020, by an external, independent Data Monitoring Committee from the Phase 3 clinical study.

Prof. Ugur Sahin, BioNTech's CEO added: “We will continue to collect further data as the trial continues to enroll for a final analysis planned when a total of 164 confirmed COVID-19 cases have accrued."

The November 9, 2020, press release indicates 'that protection is achieved 28-days after the initiation of the vaccination, which consists of a 2-dose schedule.'